Literature DB >> 6684806

Effects of long term inhaled high dose beclomethasone dipropionate on adrenal function.

M J Smith, M E Hodson.   

Abstract

Studies of adrenal function were performed on 54 asthmatic patients who were taking long term high doses of inhaled beclomethasone dipropionate ranging from 500 to 2000 micrograms/day for between six and 60 months. Of the 43 patients taking up to 1500 micrograms/day, 39 (91%) had normal basal plasma cortisol concentrations and normal short tetracosactrin responses and 24 hour urinary free cortisol excretion was within the normal range in eight of nine patients tested. Some evidence of adrenal suppression was found in patients taking 2000 micrograms/day, with basal plasma cortisol below the normal range in four out of 11 patients and 24 hour urinary free cortisol excretion below the normal range in five out of six patients tested. Only one of the 11 patients taking 2000 micrograms/day had a short tetracosactrin response below the normal range: the mean rise in plasma cortisol was, however, significantly lower in this group than in those taking 1000 micrograms/day (328 (SE 30) and 506 (34) nmol/l respectively) (p less than 0.01). Patients taking more than 1500 micrograms/day of inhaled beclomethasone may require systemic corticosteroids during prolonged stress.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6684806      PMCID: PMC459635          DOI: 10.1136/thx.38.9.676

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  10 in total

1.  Properties and therapeutic uses of some corticosteroids with enhanced topical potency.

Authors:  D M Harris
Journal:  J Steroid Biochem       Date:  1975-05       Impact factor: 4.292

2.  Response of patients receiving high dose beclomethasone dipropionate.

Authors:  J F Costello; T J Clark
Journal:  Thorax       Date:  1974-09       Impact factor: 9.139

Review 3.  Drug spotlight program: systemic corticosteroid therapy: pharmacology and endocrinologic considerations.

Authors:  J C Melby
Journal:  Ann Intern Med       Date:  1974-10       Impact factor: 25.391

4.  Aerosol beclomethasone dipropionate: a dose-response study in chronic bronchial asthma.

Authors:  J Gaddie; G R Petrie; I W Reid; C Skinner; D J Sinclair; K N Palmer
Journal:  Lancet       Date:  1973-08-11       Impact factor: 79.321

5.  The effect of oral and inhaled beclomethasone dipropionate on adrenal function.

Authors:  D M Harris; L E Martin; C Harrison; D Jack
Journal:  Clin Allergy       Date:  1973-09

6.  Inhaled steroid aerosols and alternate-day prednisone.

Authors:  M Weinberger; B Sherman
Journal:  Lancet       Date:  1979-04-21       Impact factor: 79.321

7.  Reliability of the 30-minute ACTH test in assessing hypothalamic-pituitary-adrenal function.

Authors:  J Lindholm; H Kehlet; M Blichert-Toft; B Dinesen; J Riishede
Journal:  J Clin Endocrinol Metab       Date:  1978-08       Impact factor: 5.958

8.  A graded dose assessment of the efficacy of beclomethasone dipropionate aerosol for severe chronic asthma.

Authors:  J H Toogood; N M Lefcoe; D S Haines; B Jennings; N Errington; L Baksh; L Chuang
Journal:  J Allergy Clin Immunol       Date:  1977-04       Impact factor: 10.793

9.  Beclomethasone dipropionate and chronic asthma. The effect of long-term aerosol administration on the hypothalamic-pituitary-adrenal axis after substitution for oral therapy with corticosteroids.

Authors:  S A Spitzer; H Kaufman; A Koplovitz; M Topilsky; I Blum
Journal:  Chest       Date:  1976-07       Impact factor: 9.410

10.  High-dose beclomethasone inhaler in the treatment of asthma.

Authors:  M J Smith; M E Hodson
Journal:  Lancet       Date:  1983-02-05       Impact factor: 79.321

  10 in total
  24 in total

1.  Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung.

Authors:  C Minto; B Li; B Tattam; K Brown; J P Seale; R Donnelly
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

2.  Morning serum cortisol concentrations after 2 mg inhaled beclomethasone dipropionate in normal subjects: effect of a 750 ml spacing device.

Authors:  M Farrer; A J Francis; S J Pearce
Journal:  Thorax       Date:  1990-10       Impact factor: 9.139

3.  Bone turnover during high dose inhaled corticosteroid treatment.

Authors:  N J Ali; S Capewell; M J Ward
Journal:  Thorax       Date:  1991-03       Impact factor: 9.139

Review 4.  Corticosteroid-associated tendinopathies: an analysis of the published literature and spontaneous pharmacovigilance data.

Authors:  Irene Blanco; Stephan Krähenbühl; Raymond G Schlienger
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 5.  Adverse effects of inhaled corticosteroids.

Authors:  R J Stead; N J Cooke
Journal:  BMJ       Date:  1989-02-18

Review 6.  The place of high-dose inhaled corticosteroids in asthma therapy.

Authors:  M J Smith
Journal:  Drugs       Date:  1987-05       Impact factor: 9.546

7.  A self management plan in the treatment of adult asthma.

Authors:  R Beasley; M Cushley; S T Holgate
Journal:  Thorax       Date:  1989-03       Impact factor: 9.139

Review 8.  Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-08       Impact factor: 9.546

9.  Large volume spacer devices and the influence of high dose beclomethasone dipropionate on hypothalamo-pituitary-adrenal axis function.

Authors:  P H Brown; A P Greening; G K Crompton
Journal:  Thorax       Date:  1993-03       Impact factor: 9.139

10.  Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler.

Authors:  O Selroos; M Halme
Journal:  Thorax       Date:  1991-12       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.